Medication info
Febaro Tablet 2 mg (Pitavastatin Calcium Hydrate)

Febaro Tablet 2 mg (Pitavastatin Calcium Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Pitavastatin Calcium Hydrate›2mg / 1 tablet
Manufacturer / importer
Anguk Pharmaceutical Co., Ltd.
Appearance
Very light yellowish-red round film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201805361 · Approved 2018.12.28 · Insurance code 650205020

Summary

Main use
Improvement of primary hypercholesterolemia and mixed dyslipidemia
Who takes it
Adults
Adult dose
Patients must follow a standard cholesterol-lowering diet before and during treatment with this drug. The usual initial dose for adults is 1~2 mg of pitavastatin calcium once daily. If the reduction in LDL-cholesterol levels is inadequate, the dose may be increased to a maximum of 4 mg daily. Depending on LDL-cholesterol levels, treatment goals, and the patient's response, the dose should be appropriately increased or decreased at intervals of 4 weeks or longer. The therapeutic effect of this drug is maintained with continued administration.

Ingredients

Manufacturer
Anguk Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of primary hypercholesterolemia and mixed dyslipidemia

  • Primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • non-familial hypercholesterolemia
  • mixed dyslipidemia
  • elevated total cholesterol
  • increased LDL-cholesterol
  • increased apo-B protein
  • increased triglycerides
View approved original text

This medication lowers cholesterol, LDL-cholesterol, apo-B protein, and triglyceride levels while raising HDL-cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia. It helps to effectively improve blood lipid levels as a complement to dietary therapy. Therefore, it plays an important role in managing hyperlipidemia and also contributes to the prevention of cardiovascular diseases.

How to take

Adult dose

Patients must follow a standard cholesterol-lowering diet before and during treatment with this drug. The usual initial dose for adults is 1~2 mg of pitavastatin calcium once daily. If the reduction in LDL-cholesterol levels is inadequate, the dose may be increased to a maximum of 4 mg daily. Depending on LDL-cholesterol levels, treatment goals, and the patient's response, the dose should be appropriately increased or decreased at intervals of 4 weeks or longer. The therapeutic effect of this drug is maintained with continued administration.

Precautions

This drug should not be used in certain patients. It should not be administered to individuals with hypersensitivity to this drug, active liver disease, or persistent elevated liver enzyme levels of unknown origin, nor to patients with severe liver impairment or biliary obstruction. Additionally, it should not be used by patients taking cyclosporine, those with myopathy, pregnant or potentially pregnant women, nursing mothers, or children. Extreme caution should be exercised when administering this drug to individuals with renal impairment or liver dysfunction, those with excessive alcohol intake, patients taking fibrates or nicotinic acid, those with hypothyroidism, patients with a history of genetic muscle disease or myopathy, elderly patients, and patients with severe myasthenia. During treatment with this drug, abnormal symptoms such as muscle pain, weakness, abdominal pain, rash, and itching may occur, and serious muscle damage such as liver dysfunction, thrombocytopenia, or rhabdomyolysis may also occur. Therefore, it is important to regularly check blood tests and liver function tests to monitor for adverse reactions. This drug can interact with other medications, so caution should be exercised, especially when used in combination with cyclosporine, fibrates, nicotinic acid, or erythromycin, as the risk of renal function deterioration and muscle damage may be increased. In elderly patients, due to decreased physical function, the risk of adverse reactions may be higher, necessitating dosage adjustments and precautions. Pregnant or nursing women should not use this drug, and if they become pregnant while taking it, they should discontinue the medication immediately. The safety and efficacy of this medication in children have not been established, so its use is not recommended. Since this medication is used to treat hypercholesterolemia, thorough examinations should be conducted to confirm hyperlipidemia before administration, and non-pharmacological treatments such as dietary therapy and exercise should also be considered. During treatment, regular monitoring of blood lipid levels should be conducted to assess treatment efficacy and adverse reactions, and the drug should be discontinued immediately if abnormalities are detected. This medication should be kept out of reach of children and stored in its original container to prevent misuse or deterioration of quality.

Side effects

  • Abdominal pain
  • rash
  • malaise
  • paralysis
  • itching
  • myalgia
  • weakness
  • increased CPK levels
  • elevated myoglobin in blood and urine
  • acute renal failure
Show 76 more
  • liver dysfunction
  • jaundice
  • thrombocytopenia
  • urticaria
  • erythema
  • angioedema
  • increased bilirubin
  • elevated cholinesterase
  • increased AST
  • increased ALT
  • increased γ-GT
  • increased ALP
  • increased LDH
  • rigidity
  • drowsiness
  • insomnia
  • headache
  • heavy head sensation
  • dizziness
  • dry mouth
  • dyspepsia
  • abdominal distension
  • constipation
  • stomatitis
  • vomiting
  • anorexia
  • glossitis
  • nausea
  • gastric discomfort
  • diarrhea
  • granulocytopenia
  • leukopenia
  • eosinophilia
  • leukocytosis
  • increased globulin
  • positive Coombs test
  • anemia
  • increased urinary frequency
  • elevated BUN
  • increased serum creatinine
  • decreased aldosterone
  • increased aldosterone
  • elevated adrenocorticotropic hormone
  • increased cortisol
  • decreased testosterone
  • muscle cramps
  • loss of strength
  • palpitations
  • fatigue
  • skin pain
  • burning sensation
  • arthralgia
  • edema
  • blurred vision
  • photophobia
  • hearing loss
  • urinary hematuria
  • increased uric acid levels
  • elevated serum potassium and phosphorus
  • taste disturbances
  • sleep disorders
  • memory loss
  • depression
  • interstitial lung disease
  • sexual dysfunction
  • diabetes
  • immune-mediated necrotizing myopathy
  • myasthenia gravis
  • ocular myasthenia
  • facial edema
  • arm edema
  • hypersensitivity
  • skin paresthesia
  • loss of appetite
  • increased blood pressure
  • chest discomfort

Not everyone experiences these, and they can vary from person to person.

Storage

This drug is sensitive to light, so it should be stored in a tightly closed container that protects it from light. Additionally, it is best stored at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

Very light yellowish-red round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.